Search

Your search keyword '"Naftali T."' showing total 155 results
Start Over Author "Naftali T."
155 results on '"Naftali T."'

1. Pentacarbonyl{3-[(2S)-1-methylpyrrolidin-2-yl]pyridine}tungsten(0)

Author

Martin O. Onani, Roger A. Lalancette, Naftali T. Muriithi, Eunice A. Nyawade, and Boitumelo V. Kgarebe

Subjects
Crystallography, QD901-999
Abstract

The title compound, [W(C10H14N2)(CO)5], contains five carbonyl ligands and a nicotine ligand in an octahedral arrangement around the tungsten atom. The metal atom shows cis angles in the range 87.30 (16)–94.2 (2)°, and trans angles between 175.2 (2) and 178.1 (4)°. The W—CO bond trans to the pyridine N atom [1.987 (6) Å] is noticeably shorter than the others, which range between 2.036 (3) and 2.064 (3) Å, possibly due to the well-known trans effect. The distance between the W atom and the pyridine N atom is 2.278 (4) Å.

Published
2010
Full Text
View/download PDF

3. DOP29 Capsule endoscopy-guided proactive treatment versus standard treatment of patients with quiescent Crohn’s Disease: The CURE-CD randomized controlled trial

Author

Ben-Horin, S, primary, Lahat, A, additional, Ungar, B, additional, Ukashi, O, additional, Yablecovitch, D, additional, Amitai, M M, additional, Haberman, Y, additional, Selinger, L, additional, Talan-Asher, A, additional, Kriger-Sharabi, O, additional, Naftali, T, additional, Ron, Y, additional, Yanai, H, additional, Dotan, I, additional, Kopylov, U, additional, and Eliakim, R, additional

Published
2024
Full Text
View/download PDF

5. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.

Author

Yanai, H., Kagramanova, A., Knyazev, O., Sabino, J., Haenen, S., Mantzaris, G.J., Mountaki, K., Armuzzi, A., Pugliese, D., Furfaro, F., Fiorino, G., Drobne, D., Kurent, T., Yassin, S., Maharshak, N., Castiglione, F., Sire, R. de, Nardone, O.M., Farkas, K., Molnar, T., Krznaric, Z., Brinar, M., Chashkova, E., Livne Margolin, M., Kopylov, U., Bezzio, C., Bar-Gil Shitrit, A., Lukas, M., Chaparro, M., Truyens, M., Nancey, S., Lobaton, T., Gisbert, J.P., Saibeni, S., Bacsúr, P., Bossuyt, P., Schulberg, J., Hoentjen, F., Viganò, C., Palermo, A., Torres, J., Revés, J., Karmiris, K., Velegraki, M., Savarino, E., Markopoulos, P., Tsironi, E., Ellul, P., Calviño Suárez, C., Weisshof, R., Ben-Hur, D., Naftali, T., Eriksson, C., Koutroubakis, I.E., Foteinogiannopoulou, K., Limdi, J.K., Liu, E., Surís, G., Calabrese, E., Zorzi, F., Filip, R., Ribaldone, D.G., Snir, Y., Goren, I., Banai-Eran, H., Broytman, Y., Amir Barak, H., Avni-Biron, I., Ollech, J.E., Dotan, I., haroni Golan, M. A, Yanai, H., Kagramanova, A., Knyazev, O., Sabino, J., Haenen, S., Mantzaris, G.J., Mountaki, K., Armuzzi, A., Pugliese, D., Furfaro, F., Fiorino, G., Drobne, D., Kurent, T., Yassin, S., Maharshak, N., Castiglione, F., Sire, R. de, Nardone, O.M., Farkas, K., Molnar, T., Krznaric, Z., Brinar, M., Chashkova, E., Livne Margolin, M., Kopylov, U., Bezzio, C., Bar-Gil Shitrit, A., Lukas, M., Chaparro, M., Truyens, M., Nancey, S., Lobaton, T., Gisbert, J.P., Saibeni, S., Bacsúr, P., Bossuyt, P., Schulberg, J., Hoentjen, F., Viganò, C., Palermo, A., Torres, J., Revés, J., Karmiris, K., Velegraki, M., Savarino, E., Markopoulos, P., Tsironi, E., Ellul, P., Calviño Suárez, C., Weisshof, R., Ben-Hur, D., Naftali, T., Eriksson, C., Koutroubakis, I.E., Foteinogiannopoulou, K., Limdi, J.K., Liu, E., Surís, G., Calabrese, E., Zorzi, F., Filip, R., Ribaldone, D.G., Snir, Y., Goren, I., Banai-Eran, H., Broytman, Y., Amir Barak, H., Avni-Biron, I., Ollech, J.E., Dotan, I., and haroni Golan, M. A

Abstract

Item does not contain fulltext, BACKGROUND: Endoscopic-post-operative-recurrence [ePOR] in Crohn's disease [CD] after ileocecal resection [ICR] is a major concern. We aimed to evaluate the effectiveness of early prophylaxis with biologics and to compare anti-tumour necrosis factor [anti-TNF] therapy to vedolizumab [VDZ] and ustekinumab [UST] in a real-world setting. METHODS: A retrospective multicentre study of CD-adults after curative ICR on early prophylaxis was undertaken. ePOR was defined as a Rutgeerts score [RS] ≥ i2 or colonic-segmental-SES-CD ≥ 6. Multivariable logistic regression was used to evaluate risk factors, and inverse probability treatment weighting [IPTW] was applied to compare the effectiveness between agents. RESULTS: The study included 297 patients (53.9% males, age at diagnosis 24 years [19-32], age at ICR 34 years [26-43], 18.5% smokers, 27.6% biologic-naïve, 65.7% anti-TNF experienced, 28.6% two or more biologics and 17.2% previous surgery). Overall, 224, 39 and 34 patients received anti-TNF, VDZ or UST, respectively. Patients treated with VDZ and UST were more biologic experienced with higher rates of previous surgery. ePOR rates within 1 year were 41.8%. ePOR rates by treatment groups were: anti-TNF 40.2%, VDZ 33% and UST 61.8%. Risk factors for ePOR at 1 year were: past-infliximab (adjusted odds ratio [adj.OR] = 1.73 [95% confidence interval, CI: 1.01-2.97]), past-adalimumab [adj.OR = 2.32 [95% CI: 1.35-4.01] and surgical aspects. After IPTW, the risk of ePOR within 1 year of VDZ vs anti-TNF or UST vs anti-TNF was comparable (OR = 0.55 [95% CI: 0.25-1.19], OR = 1.86 [95% CI: 0.79-4.38]), respectively. CONCLUSION: Prevention of ePOR within 1 year after surgery was successful in ~60% of patients. Patients treated with VDZ or UST consisted of a more refractory group. After controlling for confounders, no differences in ePOR risk were seen between anti-TNF prophylaxis and other groups.

Published
2022

9. DOP016 Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of inflammatory bowel diseases: results from the multicenter European TEDDY study

Author

Chaparro, M., Verreth, A., Lobaton, T., Gravito-Soares, E., Julsgaard, M., Savarino, E., Magro, F., Avni Biron, I., Lpez-Serrano, P., Casanova, M., Gompertz, M., Vitor, S., Arroyo, M., Pugliese, D., Zabana, Y., Vicente, R., Aguas, M., Bar-Gil Shitrit, A., Gutierrez, A., Doherty, G., Fernández-Salazar, L., Martinez Cadilla, J., Huguet, J., OʼToole, A., Stasi, E., Manceñido Marcos, N., Villoria, A., Karmiris, K., Rahier, J., Rodriguez, C., Diz-Lois Palomares, M., Fiorino, G., Benítez, J., Principi, M., Naftali, T., Taxonera, C., Mantzaris, G., Sebkova, L., Iade, B., Lissner, D., Ferrer Bradley, I., Lpez-San Román, A., Marín-Jiménez, I., Merino, O., Sierra, M., Van Domselaar, M., Caprioli, F., Guerra, I., Peixe, P., Piqueras, M., Rodríguez-Lago, I., Ber, Y., Van Hoeve, K., Torres, P., Gravito-Soares, E., Rudbeck-Thomsen, D., Bartolo, O., Peixoto, A., Martín, G., Pérez, J., Garre, A., Donday, M.G., Martín de Carpi, J., and Gisbert, J.P.

Published
2017
Full Text
View/download PDF

11. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Author

Sands BE1, Peyrin-Biroulet L1, Loftus EV Jr1, Danese S1, Colombel JF1, Törüner M1, Jonaitis L1, Abhyankar B1, Chen J1, Rogers R1, Lirio RA1, Bornstein JD1, Schreiber S1, Calvo S, Gimenez E, Resk JH, Tron EP, Al-Ansari M, Andrews J, Bampton P, Debinski H, Hendy P, Holtmann G, Leong R, Moore G, Hindryckx P, Barac T, Draganova R, Kotzev I, Marinova I, Markov M, Mihaylov Y, Pavlov D, Penkova M, Petrov A, Spassova Z, Stoyanova D, Velev E, Vladimirov B, Yanev F, Axler J, Fedorak R, Fowler S Jr, Halder S, Jairath V, Ponich T, Wong K, Baez E, Ricardo J, Velasquez M, Banic M, Bogadi I, Borzan V, Zgrablic JC, Duvnjak M, Gusej M, Krznaric Z, Cechova I, Hala T, Janu L, Kohout P, Lukas M, Machkova M, Matous J, Ulbrych J, Vanasek T, Klinge L, Rannem T, Theede K, Borissova J, Kull K, Amil M, Bouhnik Y, Gilleta C, Fumery M, Grimaud JC, Hebuterne X, Laharie D, Moreau J, Peyrin-Biroulet L, Roblin X, Baumgart D, Buening C, Dinter J, Gauss A, Kuehbacher T, Fareed Rahman K, Schiefke I, Schreiber S, Von Amim U, Zeuzem S, Leung WK, Kin Kong Li M, Altorjay I, Bene L, Lakatos P, Molnar T, Salamon A, Schnabel R, Tulassay Z, Avni Y, Barkay O, Fishman S, Goldin E, Keret D, Lahat-Zok A, Melzer E, Naftali T, Nimer A, Ovadia B, Zittan E, Andriulli A, Cappello M, Castiglione F, Danese S, Fries W, Gionchetti P, Kohn A, Maconi G, Santino M, Savarino E, Privitera A, Romano M, Vecchi M, Villa E, Cheon JH, Han DS, Jang BI, Jeen YT, Kim JS, Kim SK, Kim HJ, Kim Y, Lee KM, Lee BI, Park DI, Park YS, Song GA, Ye BD, Pokrotnieks J, Tolmanis I, Denapiene G, Kancauskas A, Jakovlevaite V, Jonaitis L, Cruz Palacios A, Larriva de Los Reyes E, Asela Lujano Nicolas L, Mendoza Fuerte E, D'Haens G, Pierik M, Van Der Woude J, Adrych K, Danilkiewicz WC, Gawdis-Wojnarska B, Hartleb M, Karczewski M, Kierkus J, Malecka-Panas E, Petryka R, Piotrowski W, Regula J, Romatowski J, Rozciecha J, Rydzewska G, Smolinski P, Walczak P, Walczak M, Wozniak-Stolarska B, Cotter J, Lopes L, Portela F, Rodrigues Carvalho J, Simona Gheorghe L, Goldis AE, Mateescu RB, Abdulkhakov R, Agafyina A, Alexeeva O, Alikhanov B, Bunkova E, Dvorkin M, Gubonina I, Kashnikov V, Livzan M, Osipenko M, Parfenov A, Pershko A, Pesegova M, Rafalskiy V, Reshetko O, Simanenkov V, Tsybulko S, Valuyskikh E, Yakovlev A, Cvetkovic M, Damjanov D, Djuranovic S, Dugalic P, Nagorni A, Svorcan P, Zdravkovic Petrovic N, Bunganic I, Gregus M, Hlavaty T, Horvath F, Domenech Morral E, Jover Martinez R, Mendoza MIV, Shieh MJ, Wei CC, Altintas E, Atug O, Gonen C, Hamzaoglu H, Hulagu S, Toruner M, Chopey I, Danyliuk S, Datsenko O, Golovchenko N, Golovchenko O, Hospodarskyy I, Ivanov V, Klymenko V, Levchenko O, Lizogub V, Mostovoy Y, Oliinyk O, Polianskyi I, Pyrohovskyi V, Shevchuk S, Ursol G, Vdovychenko V, Vyshyvanyuk V, Beales I, Brookes M, Nwokolo C, Winter J, Aggarwal A, Aguilar H, Alnoah Z, Arce-Nunez E, Arimie C, Arterburn J, Baum C, Bellaguarda E, Bock B, Boone T, Callahan N, Chapman J, Chen S, Chiorean M, Coates A, Connor M, Dellon S, Dryden G, Du Vall G, Flores L, Fogel R, Frias J, Ginsburg P, Greenberg E, Grunkemeier D, Hellstern P, Herfarth H, Hoffman B, Horst S, Idarraga S, Iskandar H, Jain R, Jenkins E, Kaufman B, Khaleq A, Khan A, Khurana S, Lake J, Leavitt J, Leman B, Lewis D, Lindenberg D, Loftus EV, Korman L, Martin J, McCullough M, McNair A, Mehta N, Mutlu E, Narayen V, Paoli-Bruno J, Perez N, Phillips R, Raijman I, Ramirez-Vega R, Randall C, Rinesmith S, Ritter T, Safdi A, Saltzman M, Sands B, Seminerio J, Schulman M, Sedghi S, Shafran I, Shankar M, Silvers D, Soloman N, Tatum H, Tepper R, Tiongco F, Valdes M, Weber J, Zhang C., Sands, Be1, Peyrin-Biroulet, L1, Loftus EV, Jr1, Danese, S1, Colombel, Jf1, Törüner, M1, Jonaitis, L1, Abhyankar, B1, Chen, J1, Rogers, R1, Lirio, Ra1, Bornstein, Jd1, Schreiber, S1, Calvo, S, Gimenez, E, Resk, Jh, Tron, Ep, Al-Ansari, M, Andrews, J, Bampton, P, Debinski, H, Hendy, P, Holtmann, G, Leong, R, Moore, G, Hindryckx, P, Barac, T, Draganova, R, Kotzev, I, Marinova, I, Markov, M, Mihaylov, Y, Pavlov, D, Penkova, M, Petrov, A, Spassova, Z, Stoyanova, D, Velev, E, Vladimirov, B, Yanev, F, Axler, J, Fedorak, R, Fowler, S Jr, Halder, S, Jairath, V, Ponich, T, Wong, K, Baez, E, Ricardo, J, Velasquez, M, Banic, M, Bogadi, I, Borzan, V, Zgrablic, Jc, Duvnjak, M, Gusej, M, Krznaric, Z, Cechova, I, Hala, T, Janu, L, Kohout, P, Lukas, M, Machkova, M, Matous, J, Ulbrych, J, Vanasek, T, Klinge, L, Rannem, T, Theede, K, Borissova, J, Kull, K, Amil, M, Bouhnik, Y, Gilleta, C, Fumery, M, Grimaud, Jc, Hebuterne, X, Laharie, D, Moreau, J, Peyrin-Biroulet, L, Roblin, X, Baumgart, D, Buening, C, Dinter, J, Gauss, A, Kuehbacher, T, Fareed Rahman, K, Schiefke, I, Schreiber, S, Von Amim, U, Zeuzem, S, Leung, Wk, Kin Kong Li, M, Altorjay, I, Bene, L, Lakatos, P, Molnar, T, Salamon, A, Schnabel, R, Tulassay, Z, Avni, Y, Barkay, O, Fishman, S, Goldin, E, Keret, D, Lahat-Zok, A, Melzer, E, Naftali, T, Nimer, A, Ovadia, B, Zittan, E, Andriulli, A, Cappello, M, Castiglione, F, Danese, S, Fries, W, Gionchetti, P, Kohn, A, Maconi, G, Santino, M, Savarino, E, Privitera, A, Romano, M, Vecchi, M, Villa, E, Cheon, Jh, Han, D, Jang, Bi, Jeen, Yt, Kim, J, Kim, Sk, Kim, Hj, Kim, Y, Lee, Km, Lee, Bi, Park, Di, Park, Y, Song, Ga, Ye, Bd, Pokrotnieks, J, Tolmanis, I, Denapiene, G, Kancauskas, A, Jakovlevaite, V, Jonaitis, L, Cruz Palacios, A, Larriva de Los Reyes, E, Asela Lujano Nicolas, L, Mendoza Fuerte, E, D'Haens, G, Pierik, M, Van Der Woude, J, Adrych, K, Danilkiewicz, Wc, Gawdis-Wojnarska, B, Hartleb, M, Karczewski, M, Kierkus, J, Malecka-Panas, E, Petryka, R, Piotrowski, W, Regula, J, Romatowski, J, Rozciecha, J, Rydzewska, G, Smolinski, P, Walczak, P, Walczak, M, Wozniak-Stolarska, B, Cotter, J, Lopes, L, Portela, F, Rodrigues Carvalho, J, Simona Gheorghe, L, Goldis, Ae, Mateescu, Rb, Abdulkhakov, R, Agafyina, A, Alexeeva, O, Alikhanov, B, Bunkova, E, Dvorkin, M, Gubonina, I, Kashnikov, V, Livzan, M, Osipenko, M, Parfenov, A, Pershko, A, Pesegova, M, Rafalskiy, V, Reshetko, O, Simanenkov, V, Tsybulko, S, Valuyskikh, E, Yakovlev, A, Cvetkovic, M, Damjanov, D, Djuranovic, S, Dugalic, P, Nagorni, A, Svorcan, P, Zdravkovic Petrovic, N, Bunganic, I, Gregus, M, Hlavaty, T, Horvath, F, Domenech Morral, E, Jover Martinez, R, Mendoza, Miv, Shieh, Mj, Wei, Cc, Altintas, E, Atug, O, Gonen, C, Hamzaoglu, H, Hulagu, S, Toruner, M, Chopey, I, Danyliuk, S, Datsenko, O, Golovchenko, N, Golovchenko, O, Hospodarskyy, I, Ivanov, V, Klymenko, V, Levchenko, O, Lizogub, V, Mostovoy, Y, Oliinyk, O, Polianskyi, I, Pyrohovskyi, V, Shevchuk, S, Ursol, G, Vdovychenko, V, Vyshyvanyuk, V, Beales, I, Brookes, M, Nwokolo, C, Winter, J, Aggarwal, A, Aguilar, H, Alnoah, Z, Arce-Nunez, E, Arimie, C, Arterburn, J, Baum, C, Bellaguarda, E, Bock, B, Boone, T, Callahan, N, Chapman, J, Chen, S, Chiorean, M, Coates, A, Connor, M, Dellon, S, Dryden, G, Du Vall, G, Flores, L, Fogel, R, Frias, J, Ginsburg, P, Greenberg, E, Grunkemeier, D, Hellstern, P, Herfarth, H, Hoffman, B, Horst, S, Idarraga, S, Iskandar, H, Jain, R, Jenkins, E, Kaufman, B, Khaleq, A, Khan, A, Khurana, S, Lake, J, Leavitt, J, Leman, B, Lewis, D, Lindenberg, D, Loftus, Ev, Korman, L, Martin, J, Mccullough, M, Mcnair, A, Mehta, N, Mutlu, E, Narayen, V, Paoli-Bruno, J, Perez, N, Phillips, R, Raijman, I, Ramirez-Vega, R, Randall, C, Rinesmith, S, Ritter, T, Safdi, A, Saltzman, M, Sands, B, Seminerio, J, Schulman, M, Sedghi, S, Shafran, I, Shankar, M, Silvers, D, Soloman, N, Tatum, H, Tepper, R, Tiongco, F, Valdes, M, Weber, J, and Zhang, C.

Published
2019

12. P522 Effectiveness of tofacitinib in a real-world Israeli cohort of patients with moderate-severe ulcerative colitis

Author

Avni Biron, I, primary, Bar-Gil Shitrit, A, additional, Koslowsky, B, additional, Kopylov, U, additional, Levartovsky, A, additional, Weisshof, R, additional, Aviv-Cohen, N, additional, Maharshak, N, additional, Hovel, D, additional, Naftali, T, additional, Goren, I, additional, Snir, I, additional, Ollech, J, additional, Banai, H, additional, Lena, B, additional, Dotan, I, additional, and Yanai, H, additional

Published
2021
Full Text
View/download PDF

13. P525 Patients’ Perception of Risks of biologic therapy During Covid-19 Pandemic in Israel Orly Lior, Ilia Sergeev, Nahum Ruhimovich, Michal Openheim, Fabiana Benjaminov, Dan Feldman, Yehuda Ringel, Timna Naftali Division of Gastroenterology and Liver Diseases, Meir Medical Center, Kfar Saba, Israel

Author

Lior, O, primary, Sergeev, I, additional, Ruhimovich, N, additional, Openheim, M, additional, Benjaminov, F, additional, Feldman, D, additional, Ringel, Y, additional, and Naftali, T, additional

Published
2021
Full Text
View/download PDF

14. P275 Course of COVID-19 in patients with Inflammatory Bowel Diseases treated with biologics: the Israeli experience

Author

Lichtenstein, L, primary, Koslowsky, B, additional, Avni-Biron, I, additional, Ovadia, B, additional, Ben-Bassat, O, additional, Naftali, T, additional, Kopylov, U, additional, Haberman, Y, additional, Banai Eran, H, additional, Eliakim, R, additional, Lahat-Zok, A, additional, Hirsch, A, additional, Zittan, E, additional, Maharshak, N, additional, Waterman, M, additional, Israeli, E, additional, Goren, I, additional, Ollech, J E, additional, Yanai, H, additional, Ungar, B, additional, Avidan, B, additional, Ben Hur, D, additional, Melamud, B, additional, Segol, O, additional, Shalem, Z, additional, Dotan, I, additional, Odes, S H, additional, Ben-Horin, S, additional, Snir, Y, additional, Milgrom, Y, additional, Broide, E, additional, Goldin, E, additional, Delgado, S, additional, Ron, Y, additional, Cohen, N A, additional, Maoz, E, additional, Zborovski, M, additional, Odeh, S, additional, Abu Freha, N, additional, and Bar-Gil Shitrit, A, additional

Published
2021
Full Text
View/download PDF

23. Long-Term Safety of In Utero Exposure to Anti-TNF alpha Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study

Author

Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, Magro F, Avni Biron I, Lopez-Serrano P, Casanova MJ, Gompertz M, Vitor S, Arroyo M, Pugliese D, Zabana Y, Vicente R, Aguas M, Bar-Gil Shitrit A, Gutierrez A, Doherty GA, Fernandez-Salazar L, Martínez Cadilla J, Huguet JM, O'Toole A, Stasi E, Manceñido Marcos N, Villoria A, Karmiris K, Rahier JF, Rodriguez C, Diz-Lois Palomares M, Fiorino G, Benitez JM, Principi M, Naftali T, Taxonera C, Mantzaris G, Sebkova L, Iade B, Lissner D, Ferrer Bradley I, Lopez-San Roman A, Marin-Jimenez I, Merino O, Sierra M, Van Domselaar M, Caprioli F, Guerra I, Peixe P, Piqueras M, Rodriguez-Lago I, Ber Y, van Hoeve K, Torres P, Gravito-Soares M, Rudbeck-Resdal D, Bartolo O, Peixoto A, Martin G, Armuzzi A, Garre A, Donday MG, Martín-de-Carpi J, and Gisbert JP

Abstract

OBJECTIVES: The long-term safety of exposure to anti-tumor necrosis factor (anti-TNF alpha) drugs during pregnancy has received little attention. We aimed to compare the relative risk of severe infections in children of mothers with inflammatory bowel disease (IBD) who were exposed to anti-TNF alpha drugs in utero with that of children who were not exposed to the drugs. METHODS: Retrospective multicenter cohort study. Exposed cohort: children from mothers with IBD receiving anti-TNF alpha medication (with or without thiopurines) at any time during pregnancy or during the 3 months before conception. Non-exposed cohort: children from mothers with IBD not treated with anti-TNF alpha agents or thiopurines at any time during pregnancy or the 3 months before conception. The cumulative incidence of severe infections after birth was estimated using Kaplan-Meier curves, which were compared using the log-rank test. Cox-regression analysis was performed to identify potential predictive factors for severe infections in the offspring. RESULTS: The study population comprised 841 children, of whom 388 (46%) had been exposed to anti-TNF alpha agents. Median follow-up after delivery was 47 months in the exposed group and 68 months in the non-exposed group. Both univariate and multivariate analysis showed the incidence rate of severe infections to be similar in non-exposed and exposed children (1.6% vs. 2.8% per person-year, hazard ratio 1.2 (95% confidence interval 0.8-1.8)). In the multivariate analysis, preterm delivery was the only variable associated with a higher risk of severe infection (2.5% (1.5-4.3)). CONCLUSIONS: In utero exposure to anti-TNF alpha drugs does not seem to be associated with increased short-term or long-term risk of severe infections in children.

Published
2018

27. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study

Author

Chaparro, M, primary, Verreth, A, additional, Lobaton, T, additional, Gravito-Soares, E, additional, Julsgaard, M, additional, Savarino, E, additional, Magro, F, additional, Biron, Avni I, additional, Lopez-Serrano, P, additional, Casanova, M J, additional, Gompertz, M, additional, Vitor, S, additional, Arroyo, M, additional, Pugliese, D, additional, Zabana, Y, additional, Vicente, R, additional, Aguas, M, additional, Shitrit, Bar-Gil A, additional, Gutierrez, A, additional, Doherty, G A, additional, Fernandez-Salazar, L, additional, Cadilla, Martínez J, additional, Huguet, J M, additional, O'Toole, A, additional, Stasi, E, additional, Marcos, Manceñido N, additional, Villoria, A, additional, Karmiris, K, additional, Rahier, J F, additional, Rodriguez, C, additional, Palomares, Diz-Lois M, additional, Fiorino, G, additional, Benitez, J M, additional, Principi, M, additional, Naftali, T, additional, Taxonera, C, additional, Mantzaris, G, additional, Sebkova, L, additional, Iade, B, additional, Lissner, D, additional, Bradley, Ferrer I, additional, Roman, Lopez-San A, additional, Marin-Jimenez, I, additional, Merino, O, additional, Sierra, M, additional, Van Domselaar, M, additional, Caprioli, F, additional, Guerra, I, additional, Peixe, P, additional, Piqueras, M, additional, Rodriguez-Lago, I, additional, Ber, Y, additional, van Hoeve, K, additional, Torres, P, additional, Gravito-Soares, M, additional, Rudbeck-Resdal, D, additional, Bartolo, O, additional, Peixoto, A, additional, Martin, G, additional, Armuzzi, A, additional, Garre, A, additional, Donday, M G, additional, de Carpi, Martín F J, additional, and Gisbert, J P, additional

Published
2018
Full Text
View/download PDF

31. How big a relief is Roski? The Tax Court said the IRS liens too heavily on estate businesses, but will the Service acquiesce? And how can practitioners respond?

Author

Rikoon, Jonathan J., Leshkowitz, Naftali T., and Brener, Liora

Subjects
Tax liens -- Laws, regulations and rules, Estate tax -- Remedies, Deferred tax (Accounting) -- Laws, regulations and rules, Close corporations -- Taxation, Estate of Roski v. Commissioner (128 T.C. No. 10 (2007)), Government regulation, Internal Revenue Code (I.R.C. 6166)
Published
2007

34. Oxidation of cyclic amines by molybdenum(II) and tungsten(II) halocarbonyls, [M(CO)4X2]2 (M = Mo, W; X = Cl, Br)

Author

Harun M. Mbuvi, Naftali T. Muriithi, Dickson Andala, and Charles O. Onindo

Subjects
Chemistry, Inorganic chemistry, Polyatomic ion, chemistry.chemical_element, General Chemistry, Medicinal chemistry, chemistry.chemical_compound, Piperazine, Molybdenum, Mass spectrum, Melting point, Amine gas treating, Piperidine, Cis–trans isomerism
Abstract

The molybdenum(II) and tungsten(II) halocarbonyls, (M(CO) 4X2)2 (M = Mo, W; X = Cl, Br) react with a large excess of the nitrogen bases, 1-methylpyrrolidine, 1-methylpiperidine, 1-ethylpiperidine and 2- ethylpiperidine to give aminecarbonyl complexes of the type M(CO) 3L3 (L= alkylamine). Excess piperidine reacts with the tungsten halocarbonyls, (W(CO) 4X2)2 (X = Cl, Br), to give the trans isomer of the complex, W(CO) 3(C 5H11 N) 3. The halogens were recovered as the amminium salts, amine, HX. The oxidized amine dimerized to form a yellow product which was recovered as an oily liquid but in very small amounts. However, in the reaction between Mo(CO) 4Br 2 and 1-ethylpiperidine, a yellow crystalline solid, with a melting point of 224 o C was recovered in sufficient amounts for elemental analysis, melting point and spectral data. Its mass spectrum showed a molecular ion peak at m + /z = 222, a clear evidence that the oxidized amine dimerizes. The cyclic dibasic amine piperazine, C 4H10 N2 is not, however, oxidized by these halocarbonyls but rather it reacts by substituting some CO groups to form products of the type, M(CO) 3(C 4H10 N2)2X2 (M = Mo, W; X = Cl, Br). Products were characterized by elemental analysis, IR, UV, 1 H NMR and mass spectrometry.

Published
2013

38. Pentacarbonyl{3-[(2S)-1-methylpyrrolidin-2-yl]pyridine}tungsten(0)

Author

Boitumelo Kgarebe, Naftali T. Muriithi, Roger A. Lalancette, Eunice A. Nyawade, and Martin O. Onani

Subjects
Metal-Organic Papers, Tungsten atom, Chemistry, Ligand, Trans effect, Atom (order theory), chemistry.chemical_element, General Chemistry, Tungsten, Condensed Matter Physics, Bioinformatics, lcsh:Chemistry, Metal, chemistry.chemical_compound, Crystallography, lcsh:QD1-999, visual_art, Pyridine, visual_art.visual_art_medium, General Materials Science, Carbon
Abstract

The title compound, [W(C10H14N2)(CO)5], contains five carbonyl ligands and a nicotine ligand in an octahedral arrangement around the tungsten atom. The metal atom shows cis angles in the range 87.30 (16)–94.2 (2)°, and trans angles between 175.2 (2) and 178.1 (4)°. The W—CO bond trans to the pyridine N atom [1.987 (6) Å] is noticeably shorter than the others, which range between 2.036 (3) and 2.064 (3) Å, possibly due to the well-known trans effect. The distance between the W atom and the pyridine N atom is 2.278 (4) Å.

Published
2010

43. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome -- a double blind, placebo-controlled, randomized study.

Author

Niv E, Naftali T, Hallak R, and Vaisman N

Abstract

BACKGROUND: It was suggested that the intestinal microflora may play a role in the pathogenesis of irritable bowel syndrome (IBS). Probiotics may ease symptoms in IBS patients by changing gut microflora, reducing mucosal inflammation and exerting antibacterial effects. AIM: To assess the short- and long-term effects of Lactobacillus reuteri administration on clinical symptoms of IBS. METHODS: This is a double blind, placebo-controlled 6-month trial. Subjects consumed 1x10(8)cfu/tablet twice a day. The clinical severity of the IBS symptoms was evaluated by the Francis Severity score and the IBS quality-of-life score at study entry and then monthly. RESULTS: In total, 54 subjects were randomized for treatment and 39 concluded the study. Both groups (treatment and placebo) improved significantly in all the studied parameters with no significant differences between groups. Two parameters, constipation and passing gases, were marginally different between the main groups (P=0.0714 and 0.0971, respectively). CONCLUSIONS: IBS symptoms did not improve with probiotic treatment with L. reuteri. A strong placebo effect and a lack of uniformity of the IBS population may have hindered a clearer demonstration of the effect. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

44. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

Author

Silvio Danese, Jean-Frederic Colombel, Milan Lukas, Javier P Gisbert, Geert D'Haens, Bu'hussain Hayee, Remo Panaccione, Hyun-Soo Kim, Walter Reinisch, Helen Tyrrell, Young S Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Meina Tao Tang, Stefan Schreiber, Nazimuddin Aboo, Tariq Ahmad, Xavier Aldeguer Mante, Matthieu Allez, Sven Almer, Romain Altwegg, Montserrat Andreu Garcia, Ramesh Arasaradnam, Sandro Ardizzone, Alessandro Armuzzi, Ian Arnott, Guy Aumais, Irit Avni-Biron, Peter Barrow, Ian Beales, Fernando Bermejo San Jose, Abraham Bezuidenhout, Livia Biancone, Michael Blaeker, Stuart Bloom, Bernd Bokemeyer, Fabrizio Bossa, Peter Bossuyt, Guillaume Bouguen, Yoram Bouhnik, Gerd Bouma, Raymond Bourdages, Arnaud Bourreille, Christian Boustiere, Tomas Brabec, Stephan Brand, Carsten Buening, Anthony Buisson, Guillaume Cadiot, Xavier Calvet Calvo, Franck Carbonnel, Daniel Carpio, Jae Hee Cheon, Naoki Chiba, Camelia Chioncel, Nicoleta-Claudia Cimpoeru, Martin Clodi, Gino Roberto Corazza, Rocco Cosintino, Jose Cotter, Thomas Creed, Fraser Cummings, Gian Luigi de' Angelis, Marc De Maeyer, Milind Desai, Etienne Desilets, Pierre Desreumaux, Olivier Dewit, Johanna Dinter, Ecaterina Daniela Dobru, Tomas Douda, Dan Lucian Dumitrascu, Matthias Ebert, Ana Echarri Piudo, Magdy Elkhashab, Chang Soo Eun, Brian Feagan, Roland Fejes, Catarina Fidalgo, Sigal Fishman, Bernard Flourié, Sharyle Fowler, Walter Fries, Csaba Fulop, Mathurin Fumery, Gyula G Kiss, Sonja Gassner, Daniel Gaya, Bastianello Germanà, Liliana Simona Gheorghe, Cyrielle Gilletta de Saint Joseph, Paolo Gionchetti, Adrian-Eugen Goldis, Raquel Gonçalves, Jean-Charles Grimaud, Tibor Gyökeres, Herve Hagege, Andrei Haidar, Heinz Hartmann, Peter Hasselblatt, Buhussain Hayee, Xavier Hebuterne, Per Hellström, Pieter Hindryckx, Helena Hlavova, Frank Hoentjen, Stefanie Howaldt, Ludek Hrdlicka, Kyu Chan Huh, Maria Isabel Iborra Colomino, Florentina Ionita-Radu, Peter Irving, Jørgen Jahnsen, ByungIk Jang, Jeroen Jansen, Seong Woo Jeon, Rodrigo Jover Martinez, Pascal Juillerat, Per Karlén, Arthur Kaser, Radan Keil, Deepak Kejariwal, Dan Keret, Reena Khanna, Dongwoo Kim, Duk Hwan Kim, Hyo-Jong Kim, Joo Sung Kim, Kueongok Kim, Kyung-Jo Kim, Sung Kook Kim, Young-Ho Kim, Jochen Klaus, Anna Kohn, Vladimir Kojecky, Ja Seol Koo, Robert Kozak, Milan Kremer, Tunde Kristof, Frederik Kruger, David Laharie, Adi Lahat-zok, Evgeny Landa, Jonghun Lee, Kang-Moon Lee, Kook Lae Lee, YooJin Lee, Frank Lenze, Wee Chian Lim, Jimmy Limdi, James Lindsay, Pilar Lopez Serrano, Edouard Louis, Stefan Lueth, Giovanni Maconi, Fazia Mana, Steven Mann, John Mansfield, Santino Marchi, Marco Marino, John Marshall, Maria Dolores Martin Arranz, Radu-Bogdan Mateescu, John McLaughlin, Simon McLaughlin, Ehud Melzer, Jessica Mertens, Paul Mitrut, Tamas Molnar, Vinciane Muls, Pushpakaran Munuswamy, Charles Murray, Timna Naftali, Visvakuren Naidoo, Yusuf Nanabhay, Lucian Negreanu, Augustin Nguyen, Thomas Ochsenkuehn, Ambrogio Orlando, Julian Panes Diaz, Maya Paritsky, Dong Il Park, Jihye Park, Luca Pastorelli, Markus Peck-Radosavljevic, Farhad Peerani, Javier Perez Gisbert, Laurent Peyrin-Biroulet, Laurence Picon, Marieke Pierik, Terry Ponich, Francisco Portela, Maartens Jeroen Prins, Istvan Racz, Khan Fareed Rahman, Jean-Marie Reimund, Max Reinshagen, Xavier Roblin, Rodolfo Rocca, Francesca Rogai, Gerhard Rogler, Agnes Salamon, Ennaliza Salazar, Zoltan Sallo, Sunil Samuel, Miquel de los Santos Sans Cuffi, Edoardo Vincenzo Savarino, Vincenzo Savarino, Guillaume Savoye, Andrada Seicean, Christian Selinger, David Martins Serra, Hang Hock Shim, SungJae Shin, Britta Siegmund, Jesse Siffledeen, Wayne Simmonds, Jan Smid, Jose Sollano, Geun Am Song, Alexander Speight, Ioan Sporea, Dirk Staessen, George Stancu, Alan Steel, David Stepek, Victor Stoica, Andreas Sturm, Gyorgy Szekely, Teck Kiang Tan, Carlos Taxonera Samso, John Thomson, Michal Tichy, Gabor Tamas Toth, Zsolt Tulassay, Marcello Vangeli, Marta Varga, Ana Vieira, Stephanie Viennot, Erica Villa, Petr Vitek, Harald Vogelsang, Petr Vyhnalek, Peter Wahab, Jens Walldorf, Byong Duk Ye, Christopher Ziady, Danese S., Colombel J.-F., Lukas M., Gisbert J.P., D'Haens G., Hayee B., Panaccione R., Kim H.-S., Reinisch W., Tyrrell H., Oh Y.S., Tole S., Chai A., Chamberlain-James K., Tang M.T., Schreiber S., Aboo N., Ahmad T., Aldeguer Mante X., Allez M., Almer S., Altwegg R., Andreu Garcia M., Arasaradnam R., Ardizzone S., Armuzzi A., Arnott I., Aumais G., Avni-Biron I., Barrow P., Beales I., Bermejo San Jose F., Bezuidenhout A., Biancone L., Blaeker M., Bloom S., Bokemeyer B., Bossa F., Bossuyt P., Bouguen G., Bouhnik Y., Bouma G., Bourdages R., Bourreille A., Boustiere C., Brabec T., Brand S., Buening C., Buisson A., Cadiot G., Calvet Calvo X., Carbonnel F., Carpio D., Cheon J.H., Chiba N., Chioncel C., Cimpoeru N.-C., Clodi M., Corazza G.R., Cosintino R., Cotter J., Creed T., Cummings F., de' Angelis G.L., De Maeyer M., Desai M., Desilets E., Desreumaux P., Dewit O., Dinter J., Dobru E.D., Douda T., Dumitrascu D.L., Ebert M., Echarri Piudo A., Elkhashab M., Eun C.S., Feagan B., Fejes R., Fidalgo C., Fishman S., Flourie B., Fowler S., Fries W., Fulop C., Fumery M., G Kiss G., Gassner S., Gaya D., Germana B., Gheorghe L.S., Gilletta de Saint Joseph C., Gionchetti P., Goldis A.-E., Goncalves R., Grimaud J.-C., Gyokeres T., Hagege H., Haidar A., Hartmann H., Hasselblatt P., Hebuterne X., Hellstrom P., Hindryckx P., Hlavova H., Hoentjen F., Howaldt S., Hrdlicka L., Huh K.C., Iborra Colomino M.I., Ionita-Radu F., Irving P., Jahnsen J., Jang B., Jansen J., Jeon S.W., Jover Martinez R., Juillerat P., Karlen P., Kaser A., Keil R., Kejariwal D., Keret D., Khanna R., Kim D., Kim D.H., Kim H.-J., Kim J.S., Kim K., Kim K.-J., Kim S.K., Kim Y.-H., Klaus J., Kohn A., Kojecky V., Koo J.S., Kozak R., Kremer M., Kristof T., Kruger F., Laharie D., Lahat-zok A., Landa E., Lee J., Lee K.-M., Lee K.L., Lee Y., Lenze F., Lim W.C., Limdi J., Lindsay J., Lopez Serrano P., Louis E., Lueth S., Maconi G., Mana F., Mann S., Mansfield J., Marchi S., Marino M., Marshall J., Martin Arranz M.D., Mateescu R.-B., McLaughlin J., McLaughlin S., Melzer E., Mertens J., Mitrut P., Molnar T., Muls V., Munuswamy P., Murray C., Naftali T., Naidoo V., Nanabhay Y., Negreanu L., Nguyen A., Ochsenkuehn T., Orlando A., Panes Diaz J., Paritsky M., Park D.I., Park J., Pastorelli L., Peck-Radosavljevic M., Peerani F., Perez Gisbert J., Peyrin-Biroulet L., Picon L., Pierik M., Ponich T., Portela F., Prins M.J., Racz I., Rahman K.F., Reimund J.-M., Reinshagen M., Roblin X., Rocca R., Rogai F., Rogler G., Salamon A., Salazar E., Sallo Z., Samuel S., Sans Cuffi M.D.L.S., Savarino E.V., Savarino V., Savoye G., Seicean A., Selinger C., Serra D.M., Shim H.H., Shin S., Siegmund B., Siffledeen J., Simmonds W., Smid J., Sollano J., Song G.A., Speight A., Sporea I., Staessen D., Stancu G., Steel A., Stepek D., Stoica V., Sturm A., Szekely G., Tan T.K., Taxonera Samso C., Thomson J., Tichy M., Toth G.T., Tulassay Z., Vangeli M., Varga M., Vieira A., Viennot S., Villa E., Vitek P., Vogelsang H., Vyhnalek P., Wahab P., Walldorf J., Ye B.D., and Ziady C.

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Population, Antibodies, Monoclonal, Humanized, Injections, Subcutaneou, Placebo, Severity of Illness Index, Gastroenterology, Young Adult, Double-Blind Method, Internal medicine, Gastrointestinal Agent, Clinical endpoint, medicine, education, Adverse effect, Aged, Aged, 80 and over, education.field_of_study, Hepatology, business.industry, Middle Aged, medicine.disease, Ulcerative colitis, Infliximab, Treatment Outcome, Etrolizumab, Concomitant, Colitis, Ulcerative, Female, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], Human, medicine.drug
Abstract

Item does not contain fulltext BACKGROUND: Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a previous phase 2 induction study, etrolizumab significantly improved clinical remission versus placebo in patients with moderately to severely active ulcerative colitis. We aimed to compare the safety and efficacy of etrolizumab with infliximab in patients with moderately to severely active ulcerative colitis. METHODS: We conducted a randomised, double-blind, double-dummy, parallel-group, phase 3 study (GARDENIA) across 114 treatment centres worldwide. We included adults (age 18-80 years) with moderately to severely active ulcerative colitis (Mayo Clinic total score [MCS] of 6-12 with an endoscopic subscore of ≥2, a rectal bleeding subscore of ≥1, and a stool frequency subscore of ≥1) who were naive to tumour necrosis factor inhibitors. Patients were required to have had an established diagnosis of ulcerative colitis for at least 3 months, corroborated by both clinical and endoscopic evidence, and evidence of disease extending at least 20 cm from the anal verge. Participants were randomly assigned (1:1) to receive subcutaneous etrolizumab 105 mg once every 4 weeks or intravenous infliximab 5 mg/kg at 0, 2, and 6 weeks and every 8 weeks thereafter for 52 weeks. Randomisation was stratified by baseline concomitant treatment with corticosteroids, concomitant treatment with immunosuppressants, and baseline disease activity. All participants and study site personnel were masked to treatment assignment. The primary endpoint was the proportion of patients who had both clinical response at week 10 (MCS ≥3-point decrease and ≥30% reduction from baseline, plus ≥1-point decrease in rectal bleeding subscore or absolute rectal bleeding score of 0 or 1) and clinical remission at week 54 (MCS ≤2, with individual subscores ≤1); efficacy was analysed using a modified intention-to-treat population (all randomised patients who received at least one dose of study drug). GARDENIA was designed to show superiority of etrolizumab over infliximab for the primary endpoint. This trial is registered with ClinicalTrials.gov, NCT02136069, and is now closed to recruitment. FINDINGS: Between Dec 24, 2014, and June 23, 2020, 730 patients were screened for eligibility and 397 were enrolled and randomly assigned to etrolizumab (n=199) or infliximab (n=198). 95 (48%) patients in the etrolizumab group and 103 (52%) in the infliximab group completed the study through week 54. At week 54, 37 (18·6%) of 199 patients in the etrolizumab group and 39 (19·7%) of 198 in the infliximab group met the primary endpoint (adjusted treatment difference -0·9% [95% CI -8·7 to 6·8]; p=0·81). The number of patients reporting one or more adverse events was similar between treatment groups (154 [77%] of 199 in the etrolizumab group and 151 [76%] of 198 in the infliximab group); the most common adverse event in both groups was ulcerative colitis (55 [28%] patients in the etrolizumab group and 43 [22%] in the infliximab group). More patients in the etrolizumab group reported serious adverse events (including serious infections) than did those in the infliximab group (32 [16%] vs 20 [10%]); the most common serious adverse event was ulcerative colitis (12 [6%] and 11 [6%]). There was one death during follow-up, in the infliximab group due to a pulmonary embolism, which was not considered to be related to study treatment. INTERPRETATION: To our knowledge, this trial is the first phase 3 maintenance study in moderately to severely active ulcerative colitis to use infliximab as an active comparator. Although the study did not show statistical superiority for the primary endpoint, etrolizumab performed similarly to infliximab from a clinical viewpoint. FUNDING: F Hoffmann-La Roche.

Published
2022

45. Prospective Observational Evaluation of the Time-Dependency of Adalimumab Immunogenicity and Drug Concentration in Ulcerative Colitis Patients: the POETIC II Study.

Author

Harnik S, Abitbol CM, Haj Natour O, Yavzori M, Fudim E, Picard O, Naftali T, Broide E, Hirsch A, Selinger L, Shachar E, Yablecovitch D, Albshesh A, Coscas D, Kopylov U, Eliakim R, Ben-Horin S, and Ungar B

Subjects
Humans, Adalimumab therapeutic use, Prospective Studies, Tumor Necrosis Factor-alpha, Colitis, Ulcerative drug therapy, Crohn Disease drug therapy
Abstract

Background and Aims: Home self-injection of the human anti-tumour necrosis alpha [anti-TNFα] monoclonal adalimumab complicates prospective serial-sampling studies. Although a recent study examined adalimumab levels and immunogenicity in Crohn's disease [CD] patients, prospective real-world data from ulcerative colitis [UC] patients are lacking., Methods: A three-monthly home-visit programme from induction was established prospectively for UC patients. Clinical scores were determined at each visit, and sera were obtained for assessment of drug and anti-adalimumab antibody levels. Calprotectin was measured using a smartphone-based app. This cohort was compared to a parallel prospective cohort of adalimumab-treated CD patients [POETIC1]., Results: Fifty UC patients starting adalimumab [median follow-up 28 weeks] were compared to 98 adalimumab-treated CD patients [median follow-up 44 weeks]. Only 11/50 UC patients [22%] continued treatment to the end of the follow-up compared with 50/98 [51%] CD patients (odds ratio [OR] = 0.27, p = 0.001). Loss of response was significantly more common in UC patients [OR = 3.2, p = 0.001]. Seventeen patients [34%] in the UC cohort developed anti-adalimumab antibodies, 9/17 [52.9%] as early as week 2. There was no difference between patient cohorts in the overall development of anti-adalimumab antibodies [34% vs 30.6%, respectively, OR = 1.67, p = 0.67], nor was there a difference in early immunogenicity [OR = 1.39, p = 0.35]. There was no difference in low drug levels [<3 µg/mL] between the two cohorts [OR = 0.87, p = 0.83]., Conclusions: Loss of response to adalimumab therapy was significantly more common in the UC compared to the CD cohort and was driven by a higher rate of non-immunogenic, pharmacodynamic parameters., (© The Author(s) 2023. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

46. Mesenchymal stem cell therapy for Crohn's perianal fistula-a real-world experience.

Author

White I, Yanai H, Avni I, Slavin M, Naftali T, Tovi S, Dotan I, and Wasserberg N

Subjects
Humans, Treatment Outcome, Immunosuppressive Agents, Crohn Disease complications, Crohn Disease therapy, Crohn Disease diagnosis, Mesenchymal Stem Cell Transplantation adverse effects, Mesenchymal Stem Cell Transplantation methods, Rectal Fistula etiology, Rectal Fistula surgery, Mesenchymal Stem Cells
Abstract

Aim: Remission rates of medically and surgically treated complex perianal fistulas in Crohn's disease are low. Recently, trials have demonstrated the potential for long-term remission with local injection of allogeneic adipose-derived mesenchymal stem cells (darvadstrocel). Our aim was to analyse outcomes from our real-world experience with this new treatment., Methods: All patients with Crohn's disease suffering complex perianal fistulas who consecutively underwent administration of darvadstrocel at two centres were followed up and evaluated. Patients were assessed for clinical remission, response, failure, and any complications during follow-up. The results of all patients with a minimum of 3 months' follow-up are presented., Results: Thirty-three patients with Crohn's disease and complex perianal fistulas were included. Of these, 20 (61%) experienced clinical remission that was maintained for a mean follow-up of 14 (3-32) months. A total of 24 of 33 (73%) experienced at least 3 months of clinical remission, with four later having recurrence (3-12 months). Among the remaining nine patients who did not experience clinical remission, two (6%) had partial remission (such as one of two fistulas closing), two (6%) showed signs of response but not remission, and five (15%) showed no signs of healing. The mean time to maintained clinical remission was 6 weeks (range 2 weeks to 6 months), and there were no severe adverse events., Conclusion: In this real-world experience, treatment of Crohn's disease complex perianal fistulas with darvadstrocel had a 61% success rate for maintained clinical remission., (© 2023 The Authors. Colorectal Disease published by John Wiley & Sons Ltd on behalf of Association of Coloproctology of Great Britain and Ireland.)

Published
2024
Full Text
View/download PDF

48. Cannabis Improves Clinical Outcomes and Quality of Life in Patients With Chronic Pouchitis.

Author

Naftali T, Bar-Lev Schleider L, Kayless H, Bromberg Z, Dotan I, and Broide E

Abstract

Many patients with ulcerative colitis after ileoanal pouch anastomosis report improvement of pouchitis with the use of cannabis. Nine patients with chronic pouchitis used 1 g/d of cannabis: 7 patients were male with average age 51 ± 16 years. Average partial pouchitis disease activity index were 11 (range 8-17), 6 (range 5-8), and 5 (range 4-8); endoscopic subscores were 7 .3 ± 2.3, 6 ± 1.1, and 4.4 ± 0.9; average bowel movements per day were 14 (range 8-20), 8 (range 2-13), and 10 (range 13-8); and quality of life increased from 72 ± 1 to 90 ± 16 and 97 ± 10 ( P = 0.001) before cannabis treatment and after 8-12 and 52 weeks, respectively. No adverse events were reported., (© 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.)

Published
2023
Full Text
View/download PDF

49. Do inflammatory bowel disease patient preferences from treatment outcomes differ by ethnicity and gender? A cross-sectional observational study.

Author

Naftali T, Richter V, Mari A, Khoury T, Shirin H, and Broide E

Abstract

Background: Inflammatory bowel disease (IBD) patients' expectations of treatment outcomes may differ by ethnicity., Aim: To investigate treatment preferences of Jewish and Arabs patients., Methods: This prospective survey ranked outcomes treatment preferences among Arab IBD patients, based on the 10 IBD-disk items compared to historical data of Jews. An anonymous questionnaire in either Arabic or Hebrew was distributed among IBD patients. Patients were required to rank 10 statements describing different aspects of IBD according to their importance to the patients as treatment goals. Answers were compared to the answers of a historical group of Jewish patients., Results: IBD-disk items of 121 Arabs were compared to 240 Jewish patients. The Jewish patients included more females, [151 (62.9%) vs 52 (43.3%); P < 0.001], higher education level ( P = 0.02), more urban residence [188 (78.3%) vs 54 (45.4%); P < 0.001], less unemployment [52 (21.7%) vs 41 (33.9%); P = 0.012], higher income level ( P < 0.001), and more in a partnership [162 (67.8%) vs 55 (45.4%); P < 0.001]. Expectations regarding disease symptoms: abdominal pain, energy, and regular defecation ranked highest for both groups. Arabs gave significantly lower rankings (range 4.29-6.69) than Jewish patients (range 6.25-9.03) regarding all items, except for body image. Compared to Arab women, Jewish women attached higher priority to abdominal pain, energy, education/work, sleep, and joint pain. Multivariable regression analysis revealed that higher patient preferences were associated with Jewish ethnicity (OR 4.77; 95%CI 2.36-9.61, P < 0.001) and disease activity. The more active the disease, the greater the odds ratio for higher ranking of the questionnaire items (1-2 attacks per year: OR 2.13; 95%CI 1.02-4.45, P = 0.043; and primarily active disease: OR 5.29; 95%CI 2.30-12.18, P < 0.001). Factors inversely associated with higher patient preference were male gender (OR 0.5; 95%CI 0.271-0.935, P = 0.030), UC (OR 0.444; 95%CI 0.241-0.819, P = 0.009), and above average income level (OR 0.267; 95%CI: 0.124-0.577, P = 0.001)., Conclusion: The highest priority for treatment outcomes was symptom relief., Patients preferences were impacted by ethnicity, gender, and socio-economic disparity. Understanding patients' priorities may improve communication and enable a personalized approach., Competing Interests: Conflict-of-interest statement: All authors report no relevant conflict of interest for this article., (©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.)

Published
2022
Full Text
View/download PDF

50. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.

Author

Yanai H, Kagramanova A, Knyazev O, Sabino J, Haenen S, Mantzaris GJ, Mountaki K, Armuzzi A, Pugliese D, Furfaro F, Fiorino G, Drobne D, Kurent T, Yassin S, Maharshak N, Castiglione F, de Sire R, Nardone OM, Farkas K, Molnar T, Krznaric Z, Brinar M, Chashkova E, Livne Margolin M, Kopylov U, Bezzio C, Bar-Gil Shitrit A, Lukas M, Chaparro M, Truyens M, Nancey S, Lobaton T, Gisbert JP, Saibeni S, Bacsúr P, Bossuyt P, Schulberg J, Hoentjen F, Viganò C, Palermo A, Torres J, Revés J, Karmiris K, Velegraki M, Savarino E, Markopoulos P, Tsironi E, Ellul P, Calviño Suárez C, Weisshof R, Ben-Hur D, Naftali T, Eriksson C, Koutroubakis IE, Foteinogiannopoulou K, Limdi JK, Liu E, Surís G, Calabrese E, Zorzi F, Filip R, Ribaldone DG, Snir Y, Goren I, Banai-Eran H, Broytman Y, Amir Barak H, Avni-Biron I, Ollech JE, Dotan I, and Aharoni Golan M

Subjects
Adult, Female, Humans, Male, Retrospective Studies, Treatment Outcome, Tumor Necrosis Factor Inhibitors therapeutic use, Ustekinumab therapeutic use, Young Adult, Biological Products therapeutic use, Crohn Disease drug therapy, Crohn Disease prevention & control, Crohn Disease surgery
Abstract

Background: Endoscopic-post-operative-recurrence [ePOR] in Crohn's disease [CD] after ileocecal resection [ICR] is a major concern. We aimed to evaluate the effectiveness of early prophylaxis with biologics and to compare anti-tumour necrosis factor [anti-TNF] therapy to vedolizumab [VDZ] and ustekinumab [UST] in a real-world setting., Methods: A retrospective multicentre study of CD-adults after curative ICR on early prophylaxis was undertaken. ePOR was defined as a Rutgeerts score [RS] ≥ i2 or colonic-segmental-SES-CD ≥ 6. Multivariable logistic regression was used to evaluate risk factors, and inverse probability treatment weighting [IPTW] was applied to compare the effectiveness between agents., Results: The study included 297 patients (53.9% males, age at diagnosis 24 years [19-32], age at ICR 34 years [26-43], 18.5% smokers, 27.6% biologic-naïve, 65.7% anti-TNF experienced, 28.6% two or more biologics and 17.2% previous surgery). Overall, 224, 39 and 34 patients received anti-TNF, VDZ or UST, respectively. Patients treated with VDZ and UST were more biologic experienced with higher rates of previous surgery. ePOR rates within 1 year were 41.8%. ePOR rates by treatment groups were: anti-TNF 40.2%, VDZ 33% and UST 61.8%. Risk factors for ePOR at 1 year were: past-infliximab (adjusted odds ratio [adj.OR] = 1.73 [95% confidence interval, CI: 1.01-2.97]), past-adalimumab [adj.OR = 2.32 [95% CI: 1.35-4.01] and surgical aspects. After IPTW, the risk of ePOR within 1 year of VDZ vs anti-TNF or UST vs anti-TNF was comparable (OR = 0.55 [95% CI: 0.25-1.19], OR = 1.86 [95% CI: 0.79-4.38]), respectively., Conclusion: Prevention of ePOR within 1 year after surgery was successful in ~60% of patients. Patients treated with VDZ or UST consisted of a more refractory group. After controlling for confounders, no differences in ePOR risk were seen between anti-TNF prophylaxis and other groups., (© The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results